Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...185186187188189190191192193194195...208209»
  • ||||||||||  AiTan (rivoceranib) / LSK BioPartners
    Journal:  Effect of silencing LASP1 on biological behaviors of oral squamous cell carcinoma cells and IC50 of three anti-tumor drugs (Pubmed Central) -  Aug 25, 2019   
    Our results demonstrated a promising antitumour activity and a manageable safety profile of SHR-1210, displayed an explicit PK evidence of the feasibility of fixed dose, and established the foundation for further exploration. LASP1 enhances cell proliferation, plate cloning, metastasis and invasion, G2/M phase transition of cell cycle, promotes lung metastasis in nude mice and docetaxel resistance of oral squamous cell carcinoma cell line HN30.
  • ||||||||||  AiTan (rivoceranib) / LSK BioPartners
    Clinical, Journal:  Efficacy and Safety of Apatinib in Treating Advanced Colorectal Cancer (Pubmed Central) -  Aug 22, 2019   
    Methods The clinical data of 16 CRC patients treated with apatinib after failure of prior lines of treatment were retrospectively analyzed in terms of objective response rate,disease control rate,progression-free survival,overall survival,adverse events,and prognostic factors. Results The efficacy was evaluable in 14 patients,among whom the objective response rate was 7.1% and the disease control rate was 50%.The median progression-free survival was 3 months(95%CI=1.57-4.42),and the median overall survival was 6.5 months(95%CI=4.10-8.89).The safety was evaluable in 16 patients,among whom the most common grade 3 adverse events were hypertensinon(37.5%)and proteinuria(25%).No grade 4 adverse event was observed.Multivariate analysis did not show any factor directly related to survival.Conclusion Apatinib may be effective in treating advanced CRC,with tolerable side effects.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment open:  A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer (clinicaltrials.gov) -  Aug 20, 2019   
    P2,  N=30, Recruiting, 
    Results The efficacy was evaluable in 14 patients,among whom the objective response rate was 7.1% and the disease control rate was 50%.The median progression-free survival was 3 months(95%CI=1.57-4.42),and the median overall survival was 6.5 months(95%CI=4.10-8.89).The safety was evaluable in 16 patients,among whom the most common grade 3 adverse events were hypertensinon(37.5%)and proteinuria(25%).No grade 4 adverse event was observed.Multivariate analysis did not show any factor directly related to survival.Conclusion Apatinib may be effective in treating advanced CRC,with tolerable side effects. Not yet recruiting --> Recruiting
  • ||||||||||  Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer (clinicaltrials.gov) -  Aug 14, 2019   
    P=N/A,  N=100, Recruiting, 
    Apatinib was found to be both effective and safe in advanced NSCLC patients without a genetic driver mutation who experienced progression after two or more lines of chemotherapy treatment. Not yet recruiting --> Recruiting | Trial completion date: Nov 2020 --> Jul 2021 | Initiation date: Dec 2018 --> Aug 2019 | Trial primary completion date: Nov 2019 --> Jul 2020
  • ||||||||||  HTI-1090 / Jiangsu Hengrui Pharma
    Trial completion:  A Trial of HTI-1090 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) -  Aug 8, 2019   
    P1,  N=18, Completed, 
    The results of this study indicated that Apatinib inhibited MCF-7 cell proliferation and invasion through AMOT/VEGFR-2 pathway. Active, not recruiting --> Completed
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Trial completion, Trial completion date, Trial primary completion date:  A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients (clinicaltrials.gov) -  Aug 8, 2019   
    P1,  N=49, Completed, 
    Recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Sep 2029 --> Aug 2019 | Trial primary completion date: Mar 2020 --> Mar 2019
  • ||||||||||  ruzinurad (SHR 4640) / Jiangsu Hengrui Pharma
    Trial completion:  Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia (clinicaltrials.gov) -  Aug 7, 2019   
    P2,  N=198, Completed, 
    Prospective randomized controlled clinical trial is warranted. Recruiting --> Completed
  • ||||||||||  AiTan (rivoceranib) / LSK BioPartners
    Clinical, Journal:  Biomimetic Metal-Organic Framework Nanoparticles for Cooperatively Combination of Antiangiogenesis and Photodynamic Therapy for Enhanced Efficacy. (Pubmed Central) -  Aug 3, 2019   
    ...A porphyrinic Zr-metal-organic framework nanoparticle is used simultaneously as the photosensitizer and the delivery vehicle of vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor apatinib...After intravenous administration, the nanoparticles selectively accumulate in tumor through homotypic targeting mediated by the biomimic decoration, and the combination of enhanced PDT and antiangiogenic drug significantly improves their tumor inhibition efficiency. This study provides an integrated solution for mechanism-based enhancement of PDT and demonstrates the encouraging potential for multifunctional nanosystem applicable for tumor therapy.
  • ||||||||||  AiTan (rivoceranib) / LSK BioPartners
    Journal:  Renal Ewing sarcoma treated with apatinib. (Pubmed Central) -  Aug 1, 2019   
    Here, we report a case of RES that rapidly developed to metastatic disease and was refractory to radiotherapy and chemotherapy; however, the case obtained a partial response based on Choi criteria by orally taking antiangiogenic drug apatinib. Our case suggests that apatinib may be a therapeutic option for RES.
  • ||||||||||  pyrotinib (HTI-1001) / Jiangsu Hengrui Medicine
    Clinical, Journal:  Pyrotinib: First Global Approval. (Pubmed Central) -  Aug 1, 2019   
    Based on positive results in a phase II trial, the drug recently received conditional approval in China for use in combination with capecitabine for the treatment of HER2-positive, advanced or metastatic breast cancer in patients previously treated with anthracycline or taxane chemotherapy. This article summarizes the milestones in the development of pyrotinib leading to this first global approval for the treatment of HER2-positive advanced breast cancer.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Ultomiris IV (ravulizumab IV) / Alexion Pharma
    Journal:  Antibodies to watch in 2019. (Pubmed Central) -  Aug 1, 2019   
    In addition, our data show that 3 product candidates (leronlimab, brolucizumab, polatuzumab vedotin) may enter regulatory review by the end of 2018, and at least 12 (eptinezumab, teprotumumab, crizanlizumab, satralizumab, tanezumab, isatuximab, spartalizumab, MOR208, oportuzumab monatox, TSR-042, enfortumab vedotin, ublituximab) may enter regulatory review in 2019...Of these, 7 (tremelimumab, spartalizumab, BCD-100, omburtamab, mirvetuximab soravtansine, trastuzumab duocarmazine, and depatuxizumab mafodotin) are being evaluated in clinical studies with primary completion dates in late 2018 and in 2019, and are thus 'antibodies to watch'. We look forward to documenting progress made with these and other 'antibodies to watch' in the next installment of this article series.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal:  Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights. (Pubmed Central) -  Jul 31, 2019   
    Although the possible availability of active agents may be a desirable option in a very poor therapeutic scenario, clinical data from the recent studies with these drugs raise yet controversial issues. The purpose of this review is to briefly summarize the results of these novel drugs focusing on the limitations that bring some shadows on their positive therapeutic results.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Trial completion date, Trial primary completion date:  Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma (clinicaltrials.gov) -  Jul 26, 2019   
    P4,  N=32, Completed, 
    No abstract available Trial completion date: Oct 2018 --> Apr 2019 | Trial primary completion date: Oct 2018 --> Feb 2019
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open:  A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma (clinicaltrials.gov) -  Jul 25, 2019   
    P2,  N=289, Recruiting, 
    Trial completion date: Oct 2018 --> Apr 2019 | Trial primary completion date: Oct 2018 --> Feb 2019 Not yet recruiting --> Recruiting
  • ||||||||||  nofazinlimab (CS1003) / CStone Pharma, CS1002 (ipilimumab biosimilar) / CStone Pharma
    Enrollment closed, Trial primary completion date, Monotherapy:  CS1002-101: A Study of CS1002 in Subjects with Advanced Solid Tumors (clinicaltrials.gov) -  Jul 25, 2019   
    P1,  N=13, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2019 --> Dec 2018